Lexicon Pharmaceuticals Inc
NASDAQ:LXRX
| Market Cap (Intraday) | 374.90M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $0.97 |
| 50-Day MA | $0.74 |
| 200-Day MA | $0.87 |
Lexicon Pharmaceuticals Inc Stock, NASDAQ:LXRX
2445 Technology Forest Boulevard, 11th floor, The Woodlands, Texas 77381-1160
United States of America
Phone: +1.281.863.3000
Number of Employees: 103
Description
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.